StockNews.com initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT - Get Free Report) in a note issued to investors on Wednesday. The firm set a "sell" rating on the biotechnology company's stock.
Separately, HC Wainwright initiated coverage on shares of vTv Therapeutics in a research report on Wednesday, April 9th. They set a "buy" rating and a $36.00 price objective for the company.
Get Our Latest Stock Report on vTv Therapeutics
vTv Therapeutics Trading Up 4.7 %
Shares of NASDAQ:VTVT traded up $0.88 on Wednesday, reaching $19.70. 15,172 shares of the company's stock were exchanged, compared to its average volume of 23,183. vTv Therapeutics has a twelve month low of $12.12 and a twelve month high of $29.19. The company has a fifty day moving average of $18.08 and a 200-day moving average of $15.97. The company has a market capitalization of $62.84 million, a price-to-earnings ratio of -4.35 and a beta of 0.81.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.32. The company had revenue of $0.02 million for the quarter.
Institutional Investors Weigh In On vTv Therapeutics
A hedge fund recently bought a new stake in vTv Therapeutics stock. JPMorgan Chase & Co. acquired a new position in shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,803 shares of the biotechnology company's stock, valued at approximately $25,000. JPMorgan Chase & Co. owned about 0.06% of vTv Therapeutics as of its most recent SEC filing. Institutional investors own 17.51% of the company's stock.
vTv Therapeutics Company Profile
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Featured Articles
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
